Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy

NCT ID: NCT01800058

Last Updated: 2020-06-26

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 68 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2018-12-21

Brief Summary

The detection and quantification of Circulating tumor cells CTCs in peripheral blood of patients with prostate adenocarcinoma may be useful at least for:

Getting a correct stratification of patients with high-risk prostate cancer (PCa).

Set the prognosis at baseline. Evaluate the response to different treatments (predictive value and monitoring).

Establish individualized therapies.

Detailed Description

Prospective analysis of biologic samples from peripheral blood of 65 patients with localized high-risk PCa (NCCN 2011) treated with RTC-3D-IMRT combined with AD.

Following the sign of the informed consent of the patient, the blood samples will be analyzed for CTCs using an immunomagnetic method based on the CellSearch system (Veridex), in 4 periods of time:

1. prior to any treatment;

2. following AD and prior to RT; and

3. following the end of RT (1-3 months afterwards).

4. six to twelve months following the end of RT in those patients with 0 CTCs in the first determination and positive CTCs in the second or third determination

Comparison between the expression of CTCs in peripheral blood before and following AD and RT will be performed. The quantification of the CTCs obtained in these phases of treatment will be correlated with the treatment results in terms of biochemical failure according to Phoenix definition, distant metastasis rate and overall survival to identify a significant prognostic relationship and to determine the potential effect of the treatment in the number of CTCs Our working group will include 65 patients because the amount is based on routine clinical activity can be safely enrolled in the project development time by the participating centers.

Conditions

Patients With High-risk Prostate Cancer

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

Circulating prostatic tumor cells in the peripheral blood

Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):

1. prior to any treatment;

2. following AD and prior to RT; and

3. following the end of RT (1-3 months afterwards).

4. six to twelve months following the end of RT in those patients with 0 CTCs in the first determination and positive CTCs in the second or third determination

The quantification of CTC in blood samples will be done with the CellSearch® system.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Patients aged > 18 with capacity to give informed consent.
• Patients with histologically confirmed prostate cancer.
• Patients with a high risk factor: PSA> 20 ng / ml, Gleason 8-10 and / or stage T3a-b, N0M0 (NCCN 2011, stage IIB-III AJCC classification 2010). Staging by: Histology-Gleason score-, PSA, TR, ECO TR, CT, MRI.
• Patients who accept radical treatment with radiotherapy.
• Patients who give written informed consent to participate in the study

Exclusion Criteria

• Any patient diagnosed with prostate cancer, which does not meet the prerequisites.
• Any patients with another malignancy diagnosed in the past 5 years (except basal cell or squamous cell carcinoma of skin).
• Any patient who has prostate biopsy performed 7 days prior to study entry.
• Patients who have received prior treatment with hormonal therapy, chemotherapy or radiotherapy.
• Patients with PSA> 100 ng / ml.
• Any situation or condition of the patient which in the opinion of the investigator, advised against participation in the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Almudena Zapatero, MD, PhD, PI

Role: PRINCIPAL_INVESTIGATOR

Radiation Oncology Department_Hospital Universitario de La Princesa

Locations

Hospital Universitario de Santiago de Compostela

Santiago de Compostela, La Coruña, Spain

Hospital Universitario de La Princesa

Madrid, , Spain

Hospital Universitario 12 de Octubre

Madrid, , Spain

Countries

Spain

References

Damber JE, Aus G. Prostate cancer. Lancet. 2008 May 17;371(9625):1710-21. doi: 10.1016/S0140-6736(08)60729-1.

Reference Type: BACKGROUND

PMID: 18486743 (View on PubMed)

Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, Park J, Shippy A. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1028-33. doi: 10.1016/j.ijrobp.2007.11.066. Epub 2008 Feb 14.

Reference Type: BACKGROUND

PMID: 18280056 (View on PubMed)

Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74. doi: 10.1016/j.ijrobp.2007.06.054. Epub 2007 Aug 31.

Reference Type: BACKGROUND

PMID: 17765406 (View on PubMed)

Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008 Feb 1;26(4):585-91. doi: 10.1200/JCO.2007.13.9881. Epub 2008 Jan 2.

Reference Type: BACKGROUND

PMID: 18172188 (View on PubMed)

Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14.

Reference Type: BACKGROUND

PMID: 18413638 (View on PubMed)

Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007 Apr 1;13(7):2023-9. doi: 10.1158/1078-0432.CCR-06-2701.

Reference Type: BACKGROUND

PMID: 17404082 (View on PubMed)

Zapatero A, Rios P, Marin A, Minguez R, Garcia-Vicente F. Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation? Clin Oncol (R Coll Radiol). 2006 Oct;18(8):600-7. doi: 10.1016/j.clon.2006.06.010.

Reference Type: BACKGROUND

PMID: 17051950 (View on PubMed)

Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005 Apr;65(4):713-8. doi: 10.1016/j.urology.2004.11.006.

Reference Type: BACKGROUND

PMID: 15833514 (View on PubMed)

Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K, Ried T, Rao C, Uhr J. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002 Jul;8(7):2073-84.

Reference Type: BACKGROUND

PMID: 12114406 (View on PubMed)

Zapatero A, Minguez R, Nieto S, Martin de Vidales C, Garcia-Vicente F. Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us? Eur Urol. 2009 Apr;55(4):902-9. doi: 10.1016/j.eururo.2008.04.076. Epub 2008 May 7.

Reference Type: BACKGROUND

PMID: 18485578 (View on PubMed)

Zapatero A, Garcia-Vicente F, Martin de Vidales C, Cruz Conde A, Ibanez Y, Fernandez I, Rabadan M. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1279-85. doi: 10.1016/j.ijrobp.2010.07.1975. Epub 2010 Oct 6.

Reference Type: BACKGROUND

PMID: 20932659 (View on PubMed)

Olivier Gomez C, Carballido Rodriguez J. [Circulating tumor cells: isolation, quantification, and relevance of their translation into clinical practice]. Actas Urol Esp. 2010 Jan;34(1):3-5. No abstract available. Spanish.

Reference Type: BACKGROUND

PMID: 20223125 (View on PubMed)

Alix-Panabieres C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res. 2008 Aug 15;14(16):5013-21. doi: 10.1158/1078-0432.CCR-07-5125.

Reference Type: BACKGROUND

PMID: 18698019 (View on PubMed)

Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med. 2006 Mar;12(3):130-9. doi: 10.1016/j.molmed.2006.01.006. Epub 2006 Feb 20.

Reference Type: BACKGROUND

PMID: 16488189 (View on PubMed)

Cabanes A, Vidal E, Aragones N, Perez-Gomez B, Pollan M, Lope V, Lopez-Abente G. Cancer mortality trends in Spain: 1980-2007. Ann Oncol. 2010 May;21 Suppl 3:iii14-20. doi: 10.1093/annonc/mdq089.

Reference Type: BACKGROUND

PMID: 20427355 (View on PubMed)

Ghossein RA, Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur J Cancer. 2000 Aug;36(13 Spec No):1681-94. doi: 10.1016/s0959-8049(00)00152-0.

Reference Type: BACKGROUND

PMID: 10959054 (View on PubMed)

Llanes L, Ferruelo A, Lujan M, Pascual C, Garcia-Mediero JM, Berenguer A. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2005;8(3):248-52. doi: 10.1038/sj.pcan.4500801.

Reference Type: BACKGROUND

PMID: 15897916 (View on PubMed)

Zapatero A, Valcarcel F, Calvo FA, Algas R, Bejar A, Maldonado J, Villa S. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol. 2005 Sep 20;23(27):6561-8. doi: 10.1200/JCO.2005.09.662.

Reference Type: BACKGROUND

PMID: 16170164 (View on PubMed)

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74. doi: 10.1016/j.ijrobp.2006.04.029.

Reference Type: BACKGROUND

PMID: 16798415 (View on PubMed)

Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006 Jun;33(3 Suppl 9):S9-14. doi: 10.1053/j.seminoncol.2006.03.016.

Reference Type: BACKGROUND

PMID: 16797376 (View on PubMed)

Bolla M, Collette L, Van Tienhoven G, et al. Ten-year results of long-term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: A phase III EORTC study. Int J Radiat Oncol Biol Phys 2008;72:S30-S31.

Reference Type: BACKGROUND

Resel Folkersma L, Olivier Gomez C, San Jose Manso L, Veganzones de Castro S, Galante Romo I, Vidaurreta Lazaro M, de la Orden GV, Arroyo Fernandez M, Diaz Rubio E, Silmi Moyano A, Maestro de Las Casas MA. Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation. Arch Esp Urol. 2010 Jan-Feb;63(1):23-31.

Reference Type: BACKGROUND

PMID: 20157216 (View on PubMed)

Zapatero A, Gomez-Caamano A, Cabeza Rodriguez MA, Muinelo-Romay L, Martin de Vidales C, Abalo A, Calvo Crespo P, Leon Mateos L, Olivier C, Vega Piris LV. Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study. Radiat Oncol. 2020 Jun 1;15(1):137. doi: 10.1186/s13014-020-01577-5.

Reference Type: RESULT

PMID: 32487218 (View on PubMed)

A. Zapatero, A. Gomez Caamaño, M. D. L. A. Cabeza Rodriguez, L. Muinelo-Romay, C. Martin de Vidales C, A. Abalo, et al. Monitoring of Circulating Tumor Cells in Patients With High-Risk Nonmetastatic Prostate Cancer Treated With Radiation Therapy and Hormones: Preliminary Data of an Observational Prospective Phase 2 Study. International Journal of Radiation Oncology • Biology • Physics, Vol. 99, Issue 2, E280

Reference Type: RESULT

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

CaPr-RTCTC-01/PI 197

Identifier Type: -

Identifier Source: org_study_id